Varian and the Cincinnati Children's/UC Health Proton Therapy Center Announce Initial Patient Treated in the FAST-01 First Human Clinical Trial of FLASH Therapy for Cancer | Varian

Varian and the Cincinnati Children's/UC Health Proton Therapy Center Announce Initial Patient Treated in the FAST-01 First Human Clinical Trial of FLASH Therapy for Cancer

PALO ALTO, Calif., and CINCINNATI, Ohio, Nov. 19, 2020 /PRNewswire/ -- Varian (NYSE: VAR) and the Cincinnati Children's/UC Health Proton Therapy Center today announce the start of the first clinical trial of FLASH therapy as part of the recently opened FAST-01 study (FeAsibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases). The clinical trial involves the investigational use of Varian's ProBeam® particle accelerator modified to enable radiation therapy delivery at ultra-high dose rates (dose delivered in less than 1 second) and is being conducted at the Cincinnati Children's/UC Health Proton Therapy Center with John C. Breneman M.D., Medical Director of the center, serving as principal investigator.

The first clinical trial patient was treated this week. The FAST-01 study is expected to enroll up to 10 patients with bone metastases to evaluate clinical workflow feasibility, treatment-related side effects, and efficacy of treatment as assessed by measuring pain relief of trial participants. The clinical trial, informed by years of preclinical work, was designed by experts at Varian and multiple centers in the FlashForward™ Consortium, including Cincinnati's Children's/UC Health Proton Therapy Center and the New York Proton Center.

First Human Clinical Trial of FLASH Therapy for Cancer

"Treating the first patient in this FLASH clinical trial is a milestone that many thought was still years ahead of us," said Kolleen Kennedy, Chief Growth Officer and President of Proton Therapy Solutions at Varian. "There was overwhelming support from Dr. Breneman and his team for this clinical trial, which was designed in collaboration with the FlashForward Consortium and with significant contributions from the New York Proton Center. These efforts help Varian safely advance potential therapy options towards our vision of a world without fear of cancer."

Breneman noted that, because this is the first in human trial of FLASH radiotherapy, it will build a foundation for extending this therapy to other types of cancer treatments.

"Trials using FLASH radiotherapy for lung cancer and other malignancies are currently being developed," said Breneman, a UC Health radiation oncologist and a professor emeritus at the University of Cincinnati College of Medicine. "Using FLASH treatment for these cancers could deliver higher cancer-killing doses without causing inordinate side effects, which would be a real advance."

"FLASH therapy has the potential to be practice changing and dramatically improve the experience of cancer care for a new generation of patients. The launch of the first FLASH clinical trial, a project that has come to fruition after years of intensive study, is an important milestone in the progress of radiation therapy," said FlashForward Consortium member Dr. Charles B. Simone, II, FACRO, Chief Medical Officer at New York Proton Center. "We are optimistic that the results of the FAST clinical development program will transform the way the industry approaches treatment. The New York Proton Center is proud to be a partner in this future-focused study."

John Perentesis, MD, Director of the Division of Oncology & Cancer Programs at Cincinnati Children's, said FLASH is potentially a transformational advance for cancer treatment for many patients."If the side effects of radiation on the normal tissues surrounding a tumor can be significantly reduced, the dose of radiation to treat a cancer can be greatly increased," Perentesis said. "This would raise hope to cure malignancies that respond to radiation but aren't completely cured at current doses, including pediatric brain tumors like DIPG/pontine glioma and medulloblastoma, sarcomas, and neuroblastoma." 

About Varian
At Varian, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 10,000 employees across 70 locations keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

About the Cincinnati Children's/UC Health Proton Therapy Center
The Cincinnati Children's/UC Health Proton Therapy Center, which opened in 2016, is one of only 35 in the United States. The Cincinnati center incorporates a $24 million, one-of-a-kind research facility, which includes a fully operational proton treatment room dedicated for just research along with integrated laboratories. The unique capabilities of the research center were instrumental in Cincinnati developing the world's first clinical trial of FLASH proton therapy. In addition, children and adults from around the world seek treatment for more than 30 types of cancer in two clinical therapy rooms at the center.

About New York Proton Center
The New York Proton Center is creating the gold standard for proton therapy, giving new hope to patients living with cancer. In partnership with leading academic medical centers—Memorial Sloan Kettering Cancer Center, Montefiore Health System, Mount Sinai Health System, and ProHEALTH as manager—the New York Proton Center brings together expert oncologists, clinical care teams, and researchers to improve cancer care and advance the clinical evidence for proton therapy.

About ProBeam®Varian's ProBeam proton therapy system is a cancer treatment system that uses protons rather than X-rays to treat cancerous tumors with great precision. It is effective for certain types of cancers and can treat with a high dose of radiation to the tumor, while delivering lower radiation to the surrounding healthy tissue.

Press Contacts
Aimee Corso
Health + Commerce on behalf of Varian
+1 (310) 780-2661
aimee@healthandcommerce.com


Barrett J. Brunsman
Cincinnati Children's
Barrett.brunsman@CCHMC.org

Nathaniel Goehring
+1 (781) 608-8437
BerlinRosen on behalf of NY Proton
Therapy Center
nathaniel.goehring@berlinrosen.com

 

Investor Relations Contact
Anshul Maheshwari
Vice President, Investor Relations
+1 (650) 424-5631
investors@varian.com

SOURCE Varian